Systematic review finds more clinical harm than benefits in Alzheimer ’s “treatments” lecanemab, aducanumab, and donanemab
CONCLUSIONS: Although monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales in patients with Alzheimer dementia, these improvements are far below the MCID for each outcome and are accompanied by clinically meaningful harms.
The Study in Context:
Should doctors prescribe lecanemab (Leqembi) to women? The answer, given available evidence, is probably No
First, do no harm? Six reasons to approach anti-amyloid drug Aduhelm cautiously, if at all
Report: 35% of worldwide dementia cases could be prevented by modifying these 9 modifiable risk factors
The post Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab appeared first on SharpBrains.
Source: SharpBrains - Category: Neuroscience Authors: SharpBrains Tags: Brain/ Mental Health aducanumab Alzheimer's drug Alzheimers-treatment brain bleeds brain swelling cognition dementia donanemab FDA lecanemab Leqembi Medicare Mini-Mental State test minimal clinically important difference mono Source Type: blogs
More News: Alzheimer's | Brain | Dementia | Epidemiology | Georgia Health | Hemorrhagic Stroke | International Medicine & Public Health | Medicare | Men | Neurology | Neuroscience | Study | Women